AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
  • Age: Between 1 Year(s) - 21 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Newly diagnosed de novo ALL (B-ALL or T-ALL) with definitive evidence of BCR-ABL1 fusion by karyotype, FISH and/or RT-PCR.

You may not be eligible for this study if the following are true:

  • 1) Known history of chronic myelogenous leukemia (CML). 2) ALL developing after a previous cancer treated with cytotoxic chemotherapy. 3) Active, uncontrolled infection or active systemic illness that requires ongoing vasopressor support or mechanic


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.